Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.43 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309493 | 0.95 | GRM2 (0.51) | GRM2SLC9A1MPOTLR8 | |
| SCHEMBL24134933 | 0.86 | SLC9A1 (0.44) | GRM2SLC9A1KDM4E | |
| SCHEMBL18070761 | 0.83 | GRM2 (0.51) | GRM2SLC9A1KDM4E | |
| SCHEMBL20608120 | 0.81 | TDO2 (0.40) | GRM2KDM4E | |
| SCHEMBL29561346 | 0.81 | TDO2 (0.40) | GRM2KDM4E | |
| SCHEMBL15687500 | 0.79 | SLC9A1 (0.41) | GRM2SLC9A1MPOKDM4EPGR | |
| SCHEMBL19048450 | 0.78 | SLC9A1 (0.40) | GRM2SLC9A1PGRRORARORC | |
| SCHEMBL309237 | 0.77 | TLR8 (0.50) | SLC9A1TLR8 | |
| SCHEMBL27745777 | 0.77 | GRM2 (0.37) | GRM2KDM4E | |
| SCHEMBL29527486 | 0.76 | GRM2 (0.55) | GRM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307733-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3307733-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-107849031-B | Mannose derivatives for the treatment of bacterial infections | 沃泰克斯药物股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-10407414-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407414-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180244658-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2018-08-30 | — | — | US | disclosed |
| WO-2016199105-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407414-B2 | Mannose derivatives for treating bacterial infections | MANBA, MAN2A1, MPDU1 | GRM2 3437/4885SLC9A1 2602/4885MPO 214/4885 |
| US-20180244658-A1 | Mannose Derivatives for Treating Bacterial Infections | MANBA, MAN2A1, MPDU1 | GRM2 3437/4885SLC9A1 2602/4885MPO 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.